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1. INTRODUCTION {#jcla23336-sec-0005}
===============

For the patients with chronic kidney disease (CKD), which is defined as an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m^2^ for 3 months, the most frequently encountered cause of death is cardiovascular diseases (CVD),[^1^](#jcla23336-bib-0001){ref-type="ref"}, [^2^](#jcla23336-bib-0002){ref-type="ref"}, [^3^](#jcla23336-bib-0003){ref-type="ref"} such as myocardial infarction and heart failure. A large cohort study comprising \>130 000 elderly participates showed that increased incidence of cardiovascular events was related to the renal insufficiency.[^4^](#jcla23336-bib-0004){ref-type="ref"}

The diagnosis of CVD is usually based on clinical manifestation, electrocardiographic (ECG) changes, and positive cardiac biomarkers. Cardiac biomarkers, such as cardiac troponin I (cTnI),[^5^](#jcla23336-bib-0005){ref-type="ref"}, [^6^](#jcla23336-bib-0006){ref-type="ref"} creatine kinase (CK),[^6^](#jcla23336-bib-0006){ref-type="ref"} CK‐MB,[^7^](#jcla23336-bib-0007){ref-type="ref"} lactic dehydrogenase (LDH),[^8^](#jcla23336-bib-0008){ref-type="ref"} hydroxybutyrate dehydrogenase (HBDH),[^8^](#jcla23336-bib-0008){ref-type="ref"} and brain natriuretic peptide (BNP),[^9^](#jcla23336-bib-0009){ref-type="ref"} play important roles in the diagnosis of CVD. Among them, cTnI is a sensitive and specific marker of myocardium damage and is a widely used predictor of cardiovascular events[^10^](#jcla23336-bib-0010){ref-type="ref"} and BNP has widespread utility as an adjunct to CVD diagnosis and management.[^9^](#jcla23336-bib-0009){ref-type="ref"}

It is well known that cardiac biomarkers are often increased in patients with impaired renal function, which made the interpretation of cTnI, CK, CK‐MB, LDH, HBDH, and BNP is ambiguous and the diagnosis of CVD is challenging in patients with impaired renal function.[^11^](#jcla23336-bib-0011){ref-type="ref"} Information on the association between cardiac biomarkers and eGFR is currently limited, and the elevation of the cardiac biomarkers at a given eGFR is not well clarified, especially in child. For example, Remy et al[^12^](#jcla23336-bib-0012){ref-type="ref"} found that eGFR 60 to \<90 mL/min/1.73 m^2^ was associated with a 1.19 (1.12‐1.27) \[ratio (95%CI)\] times higher cTnI, but Tuncay et al[^13^](#jcla23336-bib-0013){ref-type="ref"} found that there was no significant relationship between eGFR and cTnI. Thus, the associations between eGFR and cardiac biomarkers need to be further evaluated.

In view of the above, we examined whether eGFR was associated with cTnI, CK, CK‐MB, LDH, HBDH, and BNP in Chinese population, including both adults and child.

2. MATERIALS AND METHODS {#jcla23336-sec-0006}
========================

2.1. Study population {#jcla23336-sec-0007}
---------------------

In total, 1210 adults and 325 child who performed serum creatinine measurement and cardiac biomarkers measurement simultaneously between December 2018 and February 2019 in Peking University First Hospital were initially reviewed retrospectively. Based on the medical record review, 398 adults were excluded due to unavailable data, pregnancy, hemodialysis, peritoneal dialysis, current acute myocardial infarction, and current unstable angina, and 110 child were excluded due to unavailable data, hemodialysis, peritoneal dialysis, and \<1 year old. Finally, 812 adults and 215 child were included. The detailed flowchart of patient recruitment was shown in Figure [1](#jcla23336-fig-0001){ref-type="fig"}. The research was in compliance with the Declaration of Helsinki and approved by the ethics committee of Peking University First Hospital (reference number: 1381).

![Schematic illustration of patient recruitment. Abbreviation: CKD‐EPI, the Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, the Modification of Diet in Renal Disease](JCLA-34-e23336-g001){#jcla23336-fig-0001}

2.2. Biochemistry biomarkers {#jcla23336-sec-0008}
----------------------------

Serum creatinine (Jaffe method) was measured by AU5800 automatic biochemical analyzer (Beckman Coulter, Inc). For adults, eGFR was calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI)equation recommended by the Kidney Disease Improving Global Outcomes (eGFR~CKD‐EPI~)[^14^](#jcla23336-bib-0014){ref-type="ref"} and the modified Modification of Diet in Renal Disease (MDRD) equation (eGFR ~MDRD~).[^15^](#jcla23336-bib-0015){ref-type="ref"} For child, eGFR was calculated with the Schwartz formula (eGFR~Schwartz~).[^16^](#jcla23336-bib-0016){ref-type="ref"}

Coupled multienzyme method (CK), lactic acid method (LDH), and α‐ketobutyric acid method (HBDH) were measured by AU5800 automatic biochemical analyzer (Beckman Coulter, Inc). CK‐MB, cTnI, and BNP were measured by chemiluminescent enzyme immunoassay with UniCel Dxl 800 Access automatic biochemical analyzer (Beckman Coulter, Inc).

2.3. Covariates {#jcla23336-sec-0009}
---------------

We collected data on age, gender, body mass index (BMI), smoking behavior, alcohol behavior, ST‐T wave abnormalities of resting 12‐lead ECG, previous coronary heart disease (CHD), previous CHD surgeries, other heart diseases, hypertension, diabetes, antihypertensive medications, lipid‐modifying medications, antiplatelet drugs, triglyceride (TG), low‐density lipoprotein‐cholesterol (LDL‐C), high‐density lipoprotein‐cholesterol (HDL‐C), and urea. For adults, smoking and alcohol behavior were categorized into never, former, and current. All the former had ceased smoking or drinking for at least 12 months. For child, smoking and alcohol behavior were categorized into never and current. Previous CHD surgeries include percutaneous coronary intervention and coronary artery bypass grafting. Other heart diseases include cardiac arrhythmia, congenital cardiovascular diseases, cardiomyopathy, rheumatic heart disease, valvular heart disease, infective endocarditis, and myocarditis. Antihypertensive medications include angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, calcium ion antagonists, and β‐adrenoceptor blockers. Lipid‐modifying medications include statins, probucol, and acipimox. Antiplatelet drugs include aspirin, clopidogrel, and ticagrelor. TG (enzymatic method), LDL‐C (surfactant method), HDL‐C (surfactant method), and urea (urease method) were measured by AU5800 automatic biochemical analyzer (Beckman Coulter, Inc). LDL‐C/HDL‐C was calculated by dividing LDL‐C by HDL‐C.

2.4. Statistical analyses {#jcla23336-sec-0010}
-------------------------

Data were statistically analyzed by the SPSS software version 21.0 for Windows (IBM). Graphs were prepared using GraphPad Prism version 6.0 (GraphPad Software). We have tried logarithmic transformation for data with non‐Gaussian distribution. Finally, data are represented as means ± standard deviations for Gaussian distribution and medians (interquartile ranges) for non‐Gaussian distribution and n (%) for categorical data. Student\'s *t* test and one‐way ANOVA test were used to compare differences between continuous data with Gaussian distribution. Mann‐Whitney *U* test and Kruskal‐Wallis test were used to compare differences between continuous data with non‐Gaussian distribution. Chi‐square (*χ* ^2^) test was used to compare differences between categorical data. Spearman correlation was performed between cardiac biomarkers and age or eGFR. A two‐tailed *P* value \< .05 was considered statistically significant.

Associations of eGFR~CKD‐EPI~ and eGFR~Schwartz~ with cTnI, CK, CK‐MB, LDH, HBDH, and BNP were evaluated with logistic regression analysis. eGFR ~CKD‐EPI~ and eGFR~Schwartz~ were analyzed as categorical variable (for eGFR~CKD‐EPI~: ≥90, 60 to \<90 and \<60 mL/min/1.73 m^2^; for eGFR~Schwartz~: ≥90 and \<90 mL/min/1.73 m^2^). According to the manufactory and laboratory verification, the elevated cutoff points of cTnI, CK, CK‐MB, LDH, HBDH, and BNP were determined as 0.03 ng/mL, 195 IU/L, 5 ng/mL, 240 IU/L, 220 IU/L, and 100 pg/mL, respectively. We have deleted the missing value because the number of missing values is small. We adjusted for potential covariates as follows: Model 1: unadjusted model; Model 2: age, gender, BMI, smoking, and alcohol behavior; Model 3: model 2 + urea, TG, LDL‐C/HDL‐C, ST‐T wave abnormalities of ECG, previous CHD, previous CHD surgeries, hypertension, and diabetes; Model 4: model 3 + antihypertensive medications, lipid‐modifying medications, antiplatelet drugs, and other heart diseases. Furthermore, we replaced eGFR~CKD‐EPI~ by eGFR~MDRD~ to repeat the analysis in adult participants.

3. RESULTS {#jcla23336-sec-0011}
==========

3.1. Characteristics of the study population {#jcla23336-sec-0012}
--------------------------------------------

Altogether, 812 adults and 215 child were included in this study finally. For adults, the mean age of participants was 60.6 ± 16.5 years, and 58.3% were male. For child, the mean age of participants was 7.9 ± 5.0 years, and 52.1% were boys.

The clinical characteristics of the adults and child population stratified according to eGFR~CKD‐EPI~ and eGFR~Schwartz~ categories were shown in Table [1](#jcla23336-tbl-0001){ref-type="table"} and Table [S1](#jcla23336-sup-0008){ref-type="supplementary-material"}, respectively. The median eGFR~CKD‐EPI~ was 80.24 mL/min/1.73 m^2^. Most participants had an eGFR~CKD‐EPI~ ≥ 90 mL/min/1.73 m^2^ (39.1%) or 60 to \<90 mL/min/1.73 m^2^ (42.4%), while 18.5% had eGFR~CKD‐EPI~ \< 60 mL/min/1.73 m^2^. The median eGFR~Schwartz~ was 99.93 mL/min/1.73 m^2^. 65.6% participants had an eGFR~Schwartz~ ≥ 90 mL/min/1.73 m^2^, and 34.4% had an eGFR~Schwartz~ \< 90 mL/min/1.73 m^2^. In adults, participants with lower eGFR had a worse CVD risk profile, such as hypertension and diabetes. Progressively higher eGFR ~CKD‐EPI~ categories were significantly associated with higher rates of previous CHD, previous CHD surgeries, medications use, and ST‐T wave abnormalities of ECG and higher urea.

###### 

Clinical characteristics of the adults participants stratified according to eGFR~CKD‐EPI~ categories[^a^](#jcla23336-note-0003){ref-type="fn"}

                                                                             Study population      eGFR~CKE‐EPI~ categories (mL/min/1.73 m^2^)   *P* values[^b^](#jcla23336-note-0004){ref-type="fn"}                         
  -------------------------------------------------------------------------- --------------------- --------------------------------------------- ------------------------------------------------------ --------------------- --------
  Number                                                                     812                   318 (39.1%)                                   344 (42.4%)                                            150 (18.5%)            
  Demographics                                                                                                                                                                                                                
  Age (y)                                                                    60.6 ± 16.5           50.4 ± 13.6                                   67.3 ± 12.9                                            66.5 ± 18.3           \<.001
  Gender                                                                                                                                                                                                                      
  Male                                                                       473 (58.3%)           196 (61.6%)                                   190 (55.2%)                                            87 (58.0%)            .248
  Female                                                                     339 (41.7%)           122 (38.4%)                                   154 (44.8%)                                            63 (42.0%)            
  BMI (kg/m^2^)                                                              24.66 ± 3.76          24.66 ± 3.92                                  24.69 ± 3.48                                           24.58 ± 4.04          .960
  Lifestyle variables                                                                                                                                                                                                         
  Smoking behavior                                                                                                                                                                                                            
  Never                                                                      532 (65.5%)           197 (61.9%)                                   237 (68.9%)                                            98 (65.3%)            .006
  Former                                                                     118 (14.5%)           38 (11.9%)                                    52 (15.1%)                                             28 (18.7%)            
  Current                                                                    162 (20.0%)           83 (26.2%)                                    55 (16.0%)                                             24 (16.0%)            
  Alcohol behavior                                                                                                                                                                                                            
  Never                                                                      598 (73.7%)           209 (65.7%)                                   274 (79.7%)                                            115 (76.7%)           \<.001
  Former                                                                     49 (6.0%)             19 (6.0%)                                     20 (5.8%)                                              10 (6.7%)             
  Current                                                                    165 (20.3%)           90 (28.3%)                                    50 (14.5%)                                             25 (16.6%)            
  Lipid                                                                                                                                                                                                                       
  TG (mmol/L)                                                                1.34 (0.88‐1.99)      1.35 (0.84‐2.10)                              1.29 (0.90‐1.83)                                       1.48 (1.02‐2.34)      .034
  LDL‐C/HDL‐C                                                                2.40 (1.84‐3.15)      2.45 (1.97‐3.21)                              2.25 (1.76‐2.96)                                       2.49 (1.83‐3.49)      .027
  Medical history                                                                                                                                                                                                             
  Previous CHD                                                               152 (18.7%)           28 (8.8%)                                     84 (24.4%)                                             40 (26.7%)            \<.001
  Previous CHD surgeries [^c^](#jcla23336-note-0005){ref-type="fn"}          77 (9.5%)             14 (4.4%)                                     41 (11.9%)                                             22 (14.7%)            \<.001
  Other heart diseases [^d^](#jcla23336-note-0006){ref-type="fn"}            157 (19.3%)           40 (12.6)                                     82 (23.8%)                                             35 (23.3%)            \<.001
  Hypertension                                                               399 (49.1%)           114 (35.8%)                                   183 (53.2%)                                            102 (68.0%)           \<.001
  Diabetes                                                                   222 (27.3%)           76 (23.9%)                                    87 (25.3%)                                             59 (39.3%)            .001
  Medications                                                                                                                                                                                                                 
  Antihypertensive medications[^e^](#jcla23336-note-0007){ref-type="fn"}     376 (46.3%)           107 (33.6%)                                   173 (50.3%)                                            96 (64.0%)            \<.001
  Lipid‐modifying medications[^f^](#jcla23336-note-0008){ref-type="fn"}      194 (23.9%)           62 (19.5%)                                    87 (25.3%)                                             45 (30.0%)            .033
  Antiplatelet drugs[^g^](#jcla23336-note-0009){ref-type="fn"}               136 (16.7%)           35 (11.0%)                                    67 (19.5%)                                             34 (22.7%)            .001
  ST‐T wave abnormalities of ECG                                             79 (9.7%)             25 (7.9%)                                     36 (10.5%)                                             18 (12.0%)            .308
  Kidney biomarkers                                                                                                                                                                                                           
  Creatine (µmol/L)                                                          95.29 ± 87.80         66.24 ± 12.33                                 80.62 ± 13.78                                          190.53 ± 172.53       \<.001
  eGFR~CKE‐EPI~ (mL/min/1.73 m^2^)                                           80.24 ± 25.26         102.90 ± 11.19                                77.04 ± 8.43                                           39.52 ± 15.95         \<.001
  eGFR~MDRD~ (mL/min/1.73 m^2^) [^h^](#jcla23336-note-0010){ref-type="fn"}   89.25 ± 37.65         114.88 ± 34.21                                77.42 ± 8.24                                           38.67 ± 16.50         \<.001
  Urea (mmol/L)                                                              5.44 (4.35‐6.99)      4.75 (3.79‐5.67)                              5.39 (4.43‐6.61)                                       10.18 (7.65‐17.40)    \<.001
  Cardiac biomarkers                                                                                                                                                                                                          
  cTnI (ng/mL)                                                               0.004 (0.001‐0.009)   0.002 (0.001‐0.005)                           0.004 (0.001‐0.009)                                    0.010 (0.005‐0.034)   \<.001
  CK (IU/L)[^i^](#jcla23336-note-0011){ref-type="fn"}                        68 (45‐104)           66 (43‐102)                                   67 (47‐99)                                             76 (45‐124)           .207
  CK‐MB (ng/mL)[^j^](#jcla23336-note-0012){ref-type="fn"}                    1.1 (0.7‐1.8)         0.9 (0.6‐1.4)                                 1.2 (0.8‐1.9)                                          1.5 (1.0‐2.3)         \<.001
  LDH (IU/L)[^k^](#jcla23336-note-0013){ref-type="fn"}                       172 (147‐208)         163 (141‐197)                                 176 (151‐207)                                          185 (152‐256)         \<.001
  HBDH (IU/L)[^l^](#jcla23336-note-0014){ref-type="fn"}                      132 (113‐161)         125 (109‐152)                                 136 (119‐160)                                          144 (118‐209)         \<.001
  BNP (pg/mL)[^m^](#jcla23336-note-0015){ref-type="fn"}                      47 (21‐133)           27 (14‐60)                                    62 (28‐147)                                            138 (54‐381)          \<.001

Abbreviations: BMI, body mass index; BNP, brain natriuretic peptide; CHD, coronary heart disease; CK, creatine kinase; cTnI, cardiac troponin I; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HBDH, hydroxybutyrate dehydrogenase; HDL‐C, high‐density lipoprotein‐cholesterol; LDH, lactic dehydrogenase; LDL‐C, low‐density lipoprotein‐cholesterol; MDRD, The Modification of Diet in Renal Disease; TG, triglyceride.

Data are represented as means ± standard deviations for Gaussian distribution, medians (interquartile ranges) for non‐Gaussian distribution, and n (%) for categorical data.

*P* values for the comparison of participants across the eGFR categories were calculated with the one‐way ANOVA test for Gaussian distributed data, Kruskal‐Wallis test for non‐Gaussian distribution, and chi‐square (χ^2^) test for categorical data.

CHD surgeries include percutaneous coronary intervention and coronary artery bypass grafting.

Other heart diseases include cardiac arrhythmia, congenital cardiovascular diseases, cardiomyopathy, rheumatic heart disease, valvular heart disease, infective endocarditis, and myocarditis.

Antihypertensive medications include angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, calcium ion antagonists, and β‐adrenoceptor blockers.

Lipid‐modifying medications include statins, probucol, and acipimox.

Antiplatelet drugs include aspirin, clopidogrel, and ticagrelor.

For eGFR calculated by MDRE equation, there are 393, 287, and 132 participants in three eGFR categories (≥90, 60 to \<90, \<60 mL/min/1.73 m^2^).

Data available for 754 participants, including 299, 320, and 135 participants in three eGFR categories (≥90, 60 to \<90, \<60 mL/min/1.73 m^2^).

Data available for 763 participants, including305, 321, and 137 participants in three eGFR categories (≥90, 60 to \<90, \<60 mL/min/1.73 m^2^).

Data available for 765 participants, including 306, 321, and 138 participants in three eGFR categories (≥90, 60 to \<90, \<60 mL/min/1.73 m^2^).

Data available for 740 participants, including 295, 316, and 129 participants in three eGFR categories (≥90, 60 to \<90, \<60 mL/min/1.73 m^2^).

Data available for 719 participants, including 281, 299, and 139 participants in three eGFR categories (≥90, 60 to \<90, \<60 mL/min/1.73 m^2^).
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Figure [S1](#jcla23336-sup-0001){ref-type="supplementary-material"} showed the distribution of CVD biochemistry biomarkers in all the participants. According to the cutoff points, 9.0%, 7.3%, 2.7%, 23.8%, 14.1%, and 28.6% patients had elevated cTnI, CK, CK‐MB, LDH, HBDH, and BNP, respectively. Spearman correlation analysis showed positive correlations between age and cTnI (*r* = .391; *P* \< .001), CK‐MB (*r* = .310; *P* \< .001), LDH (*r* = .120; *P* = .001), HBDH (*r* = .130; *P* \< .001), and BNP (*r* = .472; *P* \< .001) in adult participant (Figure [S2](#jcla23336-sup-0002){ref-type="supplementary-material"}). For child, there were negative correlations between age and CK (*r* = −0.119; *P* = .008), CK‐MB (*r* = −.490, *P* \< .001), LDH (*r* = −.542, *P* \< .001), and HBDH (*r* = −.603; *P* \< .001; Figure [S3](#jcla23336-sup-0003){ref-type="supplementary-material"}).

3.2. Association between eGFR and CVD biochemistry biomarkers {#jcla23336-sec-0013}
-------------------------------------------------------------

Participants with lower eGFR ~CKD‐EPI~ had significantly higher cTnI, CK‐MB, LDH, HBDH, and BNP (Table [1](#jcla23336-tbl-0001){ref-type="table"} and Figure [2](#jcla23336-fig-0002){ref-type="fig"}). For child, lower eGFR~Schwartz~ had significantly higher CK and CK‐MB (Table [S1](#jcla23336-sup-0008){ref-type="supplementary-material"} and Figure [3](#jcla23336-fig-0003){ref-type="fig"}).

![The boxplot of cTnI (A), CK (B), CK‐MB (C), LDH (D), HBDH (E), and BNP (F) stratified according to eGFR~CKD‐EPI~ categories in the adult participants. *P* values for the comparison of participants between the eGFR~CKD‐EPI~ categories were calculated with the Mann‐Whitney *U* test. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001; Abbreviation: BNP, brain natriuretic peptide; CK, creatine kinase; cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; HBDH, hydroxybutyrate dehydrogenase; LDH, lactic dehydrogenase](JCLA-34-e23336-g002){#jcla23336-fig-0002}

![The boxplot of cTnI (A), CK (B), CK‐MB (C), LDH (D), HBDH (E), and BNP (F) stratified according to eGFR~Schwartz~ categories in the child participants. P values for the comparison of participants between the eGFR~Schwartz~ categories were calculated with the Mann‐Whitney *U* test. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001; Abbreviation: BNP, brain natriuretic peptide; CK, creatine kinase; cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; HBDH, hydroxybutyrate dehydrogenase; LDH, lactic dehydrogenase](JCLA-34-e23336-g003){#jcla23336-fig-0003}

Spearman correlation analysis showed negative correlations between eGFR ~CKD‐EPI~ and cTnI (*r* = −.420; *P* \< .001), CK‐MB (*r* = −.276; *P* \< .001), LDH (*r* = −.193; *P* \< .001), HBDH (*r* = −0.215; *P* \< .001), and BNP (*r* = −0.450; *P* \< .001) (Table [2](#jcla23336-tbl-0002){ref-type="table"} and Figure [S4](#jcla23336-sup-0004){ref-type="supplementary-material"}). For child, there were negative correlations between eGFR~Schwartz~ and CK (*r* = −.263; *P* \< .001) and eGFR~Schwartz~ and CK‐MB (*r* = −.190; *P* = .006) (Table [3](#jcla23336-tbl-0003){ref-type="table"} and Figure [S5](#jcla23336-sup-0005){ref-type="supplementary-material"}).

###### 

Relationships between cardiac biomarkers and eGFR~CKD‐EPI~ categories

  Cardiac biomarkers   Total population   eGFR~CKE‐EPI~ categories (mL/min/1.73 m^2^)                                           
  -------------------- ------------------ --------------------------------------------- ------- -------- ------- ------ ------- ------
  cTnI (ng/mL)         −.420              \<.001                                        −.073   .195     −.159   .003   −.147   .074
  CK (IU/L)            −.072              .047                                          −.086   .140     −.031   .579   .095    .027
  CK‐MB (ng/mL)        −.276              \<.001                                        −.201   \<.001   −.103   .064   .006    .947
  LDH (IU/L)           −.193              \<.001                                        −.143   .013     −.018   .743   −.212   .012
  HBDH (IU/L)          −.215              \<.001                                        −.146   .012     −.052   .354   −.275   .002
  BNP (pg/mL)          −.450              \<.001                                        −.191   .001     −.177   .002   −.177   .038

Spearman correlation was performed to evaluate the relationships.

Abbreviations: BNP, brain natriuretic peptide; CK, creatine kinase; cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; HBDH, hydroxybutyrate dehydrogenase; LDH, lactic dehydrogenase.
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###### 

Relationships between cardiac biomarkers and eGFR ~Schwartz~ categories

  Cardiac biomarkers   Total population   eGFR~Schwartz~ categories (mL/min/1.73 m^2^)                          
  -------------------- ------------------ ---------------------------------------------- ------- ------ ------- ------
  cTnI (ng/mL)         −.034              .617                                           .014    .868   −.097   .411
  CK (IU/L)            −.263              \<.001                                         −.249   .004   .070    .559
  CK‐MB (ng/mL)        −.190              .006                                           −.031   .721   −.157   .189
  LDH (IU/L)           −.079              .253                                           −.021   .804   −.094   .430
  HBDH (IU/L)          −.080              .248                                           .061    .479   −.111   .354
  BNP (pg/mL)          −.020              .808                                           −.048   .638   −.249   .065

Spearman correlation was performed to evaluate the relationships.

Abbreviations: BNP, brain natriuretic peptide; CK, creatine kinase; cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; HBDH, hydroxybutyrate dehydrogenase; LDH, lactic dehydrogenase.

John Wiley & Sons, Ltd

A multivariate logistic regression analysis was performed with eGFR ≥ 90 mL/min/1.73 m^2^ as the reference. After adjustment for potential confounders, as compared with eGFR~CKD‐EPI~ ≥ 90 mL/min/1.73 m^2^, eGFR~CKD‐EPI~ 60 to \<90 mL/min/1.73 m^2^ showed no significant higher CVD biochemistry biomarkers, but eGFR ~CKD‐EPI~ \< 60 mL/min/1.73 m^2^ remained associated with a 2.83 (1.08‐7.41) \[ratio (95% CI)\] times higher cTnI and a 6.50 (2.32‐18.22) \[ratio (95% CI)\] times higher HBDH, but not CK, CK‐MB, LDH, and BNP (Model 4, Table [4](#jcla23336-tbl-0004){ref-type="table"}). In child, as compared with eGFR~Schwartz~ ≥ 90 mL/min/1.73 m^2^, eGFR~Schwartz~ \< 90 mL/min/1.73 m^2^ revealed no significant higher CVD biochemistry biomarkers (Model 4, Table [S2](#jcla23336-sup-0009){ref-type="supplementary-material"}).

###### 

Associations of eGFR~CKE‐EPI~ categories with biomarkers of cardiac injury

  Biomarker   Model       eGFR~CKE‐EPI~ categories (mL/min/1.73 m^2^)[^a^](#jcla23336-note-0021){ref-type="fn"}                                               
  ----------- ----------- --------------------------------------------------------------------------------------- ------ ----------- ----------- ------------ ------------
  cTnI        1           Reference                                                                               NA     2.38        1.16‐4.88   11.22        5.58‐22.54
  2           Reference   NA                                                                                      1.95   0.90‐4.22   9.22        4.34‐19.55   
  3           Reference   NA                                                                                      1.32   0.58‐2.97   2.81        1.09‐7.23    
  4           Reference   NA                                                                                      1.28   0.56‐2.93   2.83        1.08‐7.41    
  CK          1           Reference                                                                               NA     0.77        0.42‐1.41   1.07         0.50‐2.20
  2           Reference   NA                                                                                      0.71   0.36‐1.42   0.96        0.43‐2.13    
  3           Reference   NA                                                                                      0.62   0.30‐1.25   0.41        0.14‐1.17    
  4           Reference   NA                                                                                      0.59   0.29‐1.21   0.40        0.14‐1.16    
  CK‐MB       1           Reference                                                                               NA     1.14        0.35‐3.78   2.75         0.82‐9.17
  2           Reference   NA                                                                                      0.77   0.20‐3.01   1.83        0.46‐7.22    
  3           Reference   NA                                                                                      0.72   0.17‐2.99   0.97        0.16‐5.71    
  4           Reference   NA                                                                                      0.73   0.17‐3.14   1.02        0.16‐6.67    
  LDH         1           Reference                                                                               NA     0.98        0.60‐1.60   3.05         1.83‐5.09
  2           Reference   NA                                                                                      1.05   0.61‐1.82   3.36        1.91‐5.90    
  3           Reference   NA                                                                                      0.91   0.51‐1.62   2.11        0.98‐4.52    
  4           Reference   NA                                                                                      0.92   0.51‐1.66   2.10        0.96‐4.58    
  HBDH        1           Reference                                                                               NA     1.84        0.87‐3.88   7.49         3.61‐15.54
  2           Reference   NA                                                                                      2.42   1.08‐5.44   10.11       4.56‐22.38   
  3           Reference   NA                                                                                      2.01   0.86‐4.69   6.50        2.37‐17.86   
  4           Reference   NA                                                                                      2.09   0.89‐4.93   6.50        2.32‐18.22   
  BNP         1           Reference                                                                               NA     2.78        1.87‐4.11   7.84         4.93‐12.45
  2           Reference   NA                                                                                      1.50   0.96‐2.35   4.76        2.87‐7.92    
  3           Reference   NA                                                                                      1.18   0.74‐1.91   1.83        0.92‐3.63    
  4           Reference   NA                                                                                      1.13   0.69‐1.85   1.91        0.95‐3.85    

Abbreviations: BMI, body mass index; BNP, brain natriuretic peptide; CHD, coronary heart disease; CI, confidence interval; CK, creatine kinase; cTnI, cardiac troponin I;ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HBDH, hydroxybutyrate dehydrogenase; HDL‐C, high‐density lipoprotein‐cholesterol; LDL‐C, low‐density lipoprotein‐cholesterol; NA, not applicable; OR, odds ratio; TG, triglyceride.

Associations of eGFR~CKD‐EPI~ with cTnI, CK, CK‐MB, LDH, HBDH, and BNP were evaluated with logistic regression analysis. Model 1: unadjusted model; Model 2: age, gender, BMI, smoking and alcohol behavior; Model 3: model 2 + urea, TG, LDL‐C/HDL‐C, ST‐T wave abnormalities of ECG, previous CHD, previous CHD surgeries, hypertension and diabetes. Model 4: model 3 + antihypertensive medications, lipid‐modifying medications, antiplatelet drugs, and other heart diseases.
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3.3. Additional analyses with eGFR ~MDRD~ {#jcla23336-sec-0014}
-----------------------------------------

The median eGFR~MDRD~ was 89.25 mL/min/1.73 m^2^. Most participants had an eGFR~MDRD~ ≥ 90 mL/min/1.73 m^2^ (48.4%)or 60 to \<90 mL/min/1.73 m^2^ (35.3%), while 16.3% had eGFR~MDRD~ \< 60 mL/min/1.73 m^2^. Participants with lower eGFR~MDRD~ had significantly higher cTnI, CK, CK‐MB, LDH, HBDH, and BNP (Figure [S6](#jcla23336-sup-0006){ref-type="supplementary-material"}). Spearman correlation analysis showed negative correlations between eGFR~MDRD~ and cTnI (*r* = −.338; *P* \< .001), CK (*r* = −.129; *P* \< .001), CK‐MB (*r* = −.237; *P* \< .001), LDH (*r* = −.153; *P* \< .001), HBDH (*r* = −0.160; *P* \< .001), and BNP (*r* = −.334; *P* \< .001) (Table [S3](#jcla23336-sup-0010){ref-type="supplementary-material"} and Figure [S7](#jcla23336-sup-0007){ref-type="supplementary-material"}). After adjustment for potential confounders, as compared with eGFR~MDRD~ ≥ 90 mL/min/1.73 m^2^, eGFR~MDRD~ 60 to \<90 mL/min/1.73 m^2^ showed no significant higher CVD biochemistry biomarkers, but eGFR~MDRD~ \< 60 mL/min/1.73 m^2^ remained associated with a 6.18 (2.49‐15.34) \[ratio (95% CI)\] HBDH (Model 4, Table [S4](#jcla23336-sup-0011){ref-type="supplementary-material"}). When eGFR ~CKD‐EPI~ was replaced by eGFR~MDRD~, the associations of eGFR with cardiac biomarkers became weaker.

4. DISCUSSION {#jcla23336-sec-0015}
=============

In a cross‐sectional study, we demonstrated that there were negative correlations between eGFR~CKD‐EPI~ and cTnI, CK‐MB, LDH, HBDH, and BNP. After adjustment for potential confounders, as compared with eGFR~CKD‐EPI~ ≥ 90 mL/min/1.73 m^2^, eGFR~CKD‐EPI~ \< 60 mL/min/1.73 m^2^ remained associated with a 2.83 (1.08‐7.41) \[ratio (95% CI)\] times higher cTnI and a 6.50 (2.32‐18.22) \[ratio (95% CI)\] times higher HBDH. For child, there were negative correlations between eGFR~Schwartz~ and CK, and eGFR~Schwartz~ and CK‐MB. However, after adjustment for potential confounders, as compared with eGFR~Schwartz~ ≥ 90 mL/min/1.73 m^2^, eGFR~Schwartz~ \< 90 mL/min/1.73 m^2^ revealed no significant higher CVD biomarkers.

cTn, which included cTnI and cTnT, are released following myocardial injury. Both cTn are used interchangeably in clinical practice, whereas cTnT has been suggested to be more strongly dependent on renal elimination than cTnI.[^17^](#jcla23336-bib-0017){ref-type="ref"} Stronger associations of eGFR[^18^](#jcla23336-bib-0018){ref-type="ref"}, [^19^](#jcla23336-bib-0019){ref-type="ref"}, [^20^](#jcla23336-bib-0020){ref-type="ref"} and measured GFR[^21^](#jcla23336-bib-0021){ref-type="ref"} with cTnT than cTnI at levels \< 60 mL/min/1.73 m^2^ were observed even when both cTn were measured with high sensitivity assays.[^17^](#jcla23336-bib-0017){ref-type="ref"}, [^18^](#jcla23336-bib-0018){ref-type="ref"}, [^20^](#jcla23336-bib-0020){ref-type="ref"} However, Tuncay et al[^13^](#jcla23336-bib-0013){ref-type="ref"} found that there was no significant relationship between eGFR and cTnI. In this study, we found that after adjustment for potential confounders, as compared with eGFR~CKD‐EPI~ ≥ 90 mL/min/1.73 m^2^, eGFR~CKD‐EPI~ \< 60 mL/min/1.73 m^2^ remained associated with a 2.83 (1.08‐7.41) \[ratio (95% CI)\] times higher cTnI in adult participates. For child participates, eGFR~Schwartz~ \< 90 mL/min/1.73 m^2^ showed no significant negative correlations as compared with eGFR~Schwartz~ ≥ 90 mL/min/1.73 m^2^.

The population with reduced eGFR were at the highest risk for CVD.[^2^](#jcla23336-bib-0002){ref-type="ref"} There was a gradual and independent association between low eGFR and artery calcification, which is a well‐known predictor of CVD.[^22^](#jcla23336-bib-0022){ref-type="ref"} The reduced eGFR may cause myocardial injury via chronic low‐grade inflammation and endothelial dysfunction,[^23^](#jcla23336-bib-0023){ref-type="ref"} and may also reduce the renal elimination of cardiac biomarkers.[^18^](#jcla23336-bib-0018){ref-type="ref"}, [^24^](#jcla23336-bib-0024){ref-type="ref"} We could not determine the relative contributions of lower renal elimination and myocardial injury to the associations of eGFR with the cardiac biomarkers in our study. The negative correlations were also observed after adjustment for ST‐T wave abnormalities of ECG, which may indicate the lower renal elimination. However, the positive cardiac biomarkers may indicate minimal myocardial injury that is subclinical and not visible on an ECG. More and more studies[^12^](#jcla23336-bib-0012){ref-type="ref"}, [^23^](#jcla23336-bib-0023){ref-type="ref"} hold the opinion that myocardial injury involved, not only lower renal elimination. Thus, the results of our study suggested that minimal myocardial injury may contribute to the CVD mortality in the lower eGFR.

In this study, both eGFR~CKD‐EPI~ and eGFR~MDRD~ were associated with the cardiac biomarkers. Nevertheless, associations of eGFR~CKD‐EPI~ with cardiac biomarkers were stronger with eGFR~MDRD~. After adjustment for potential confounders, as compared with eGFR~CKD‐EPI~ ≥ 90 mL/min/1.73 m^2^, eGFR~CKD‐EPI~ \< 60 mL/min/1.73 m^2^ remained associated with a 2.83 (1.08‐7.41) \[ratio (95% CI)\] times higher cTnI and a 6.50 (2.32‐18.22) \[ratio (95% CI)\] times higher HBDH. For eGFR~MDRD~, as compared with eGFR~MDRD~ ≥ 90 mL/min/1.73 m^2^, eGFR~MDRD~ \< 60 mL/min/1.73 m^2^ only remained associated with a 6.18 (2.49‐15.34) \[ratio (95% CI)\] HBDH, but no cTnI. Previous study has clarified associations of eGFR with the cardiac biomarkers were stronger with GFR estimates that included cystatin C.[^12^](#jcla23336-bib-0012){ref-type="ref"} Moreover, The CKD‐EPI equation is more accurate than the MDRD equation[^14^](#jcla23336-bib-0014){ref-type="ref"} and combined creatinine‐cystatin C equation had greater precision and accuracy than the individual creatinine and cystatin C equation[^25^](#jcla23336-bib-0025){ref-type="ref"} This phenomenon may indicate that associations of eGFR with cardiac biomarkers were stronger when calculated with more accurate equation.

This study has several limitations. On the one hand, owing to the cross‐sectional design, it is difficult for us to make strong causal inferences. On the other hand, this study was intrinsically limited by its retrospective nature. So, the associations between eGFR and cardiac biomarkers need additional exploration in future studies.
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